Literature DB >> 23303178

Advance statement of consent from patients with primary CNS tumours to organ donation and elective ventilation.

Umang Jash Patel1.   

Abstract

A deficit in the number of organs available for transplantation persists even with an increase in donation rates. One possible choice of donor for organs that appears under-referred and/or unaccepted is patients with primary brain tumours. In spite of advances in the treatment of high-grade primary central nervous system (CNS) tumours, the prognosis remains dire. A working group on organs from donors with primary CNS tumours showed that the risk of transmission is small and outweighs the benefits of waiting for a normal donor, in survival and organ life-years, with caveats. This paper explores the possibility that, if information on organ donation were made available to patients and their families with knowledge of their inevitable fate, perhaps some will choose to donate. It would be explained that to achieve this, elective ventilation would be performed in their final moments. This would obviate the consent question because of an advance statement. It is accepted that these are sensitive matters and there will be logistic issues. This will need discussion with the public and other professionals, but it could increase the number of donors and can be extrapolated to encompass other primary CNS tumours.

Entities:  

Mesh:

Year:  2013        PMID: 23303178     DOI: 10.1136/medethics-2012-100996

Source DB:  PubMed          Journal:  J Med Ethics        ISSN: 0306-6800            Impact factor:   2.903


  2 in total

1.  Intensive care for organ preservation: A four-stage pathway.

Authors:  Dale Gardiner; David M Shaw; Jack K Kilcullen; Anne L Dalle Ave
Journal:  J Intensive Care Soc       Date:  2019-04-25

Review 2.  Ethical and legal implications of elective ventilation and organ transplantation: "medicalization" of dying versus medical mission.

Authors:  Paola Frati; Vittorio Fineschi; Matteo Gulino; Gianluca Montanari Vergallo; Natale Mario Di Luca; Emanuela Turillazzi
Journal:  Biomed Res Int       Date:  2014-07-14       Impact factor: 3.411

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.